Hematologic Malignancy and Therapy

Members of this program focus on the pathogenesis of lymphoma and chronic lymphocytic leukemia and their treatment. It covers research on the causes, diagnosis, prognosis, and treatment of these diseases.

Research efforts are centered on:

  • Understanding and correcting at the molecular level diseases derived from hematopoietic stem cells
  • Developing and using state-of-the-art molecular and cell biology technologies such as patient-derived xenografts, genomic editing, single cell biology; and hematopoietic cell manipulation to devise new treatments for these diseases

An inter-disciplinary collaborative team approach is used to uncover rational application of translational studies in the clinical setting.

Program Co-Leaders:
John Perentesis, MD, FAAP, is a nationally recognized expert in the development of new novel anticancer drugs and molecular therapies for pediatric and young adult cancers, and leukemia. His laboratory is researching the use of genetic research for personalizing cancer therapies by use of tumor and patient genetics. He was elected by his peer for inclusion in the Best Doctors in America from 1998 to 2016; and elected by pediatric oncologists across the country to the national committee for NCI-funded Children’s Oncology Group.
Yi Zheng, PhD, is director of the Experimental Hematology and Cancer Biology; and co-Director of the Cancer and Blood Diseases Institute at Cincinnati Children’s Hospital Medical Center. Dr. Zheng’s research is to understand the molecular mechanism and physiological impact of a class of particular intracellular signal transducers and develop novel therapeutic reagents that will interfere with their pathways which will relate to pathological conditions including cancer, inflammation, aging and blood disease.